Navidea touts Australian Alzheimer's study
Article Thumbnail ImageJuly 16, 2013 -- Radiopharmaceutical developer Navidea Biopharmaceuticals said that an Australian clinical study plans to switch the radiopharmaceutical it is using to Navidea's NAV4694 beta-amyloid imaging candidate.

To get access to this article and all of the content on, create a free account or sign-in now.

Member Sign In:
  MemberID or E-mail Address:

New Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • Instead of using carbon-11-labeled Pittsburgh Compound B (PiB) for its research initiative in Alzheimer's disease and mild cognitive impairment, the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging (AIBL) will now utilize Navidea's F-18-labeled beta-amyloid imaging agent, Navidea said.

    In other Navidea news, the company reported that Dr. Jess Emery Jones has resigned as a member of the firm's board of directors for personal reasons, effective July 9. Jones has served on the board since April 2011, and the company said it expects to undertake a process in the near future to evaluate the board's composition.

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 All Rights Reserved.